Lv75
4000 积分 2021-08-04 加入
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
3天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
3天前
已完结
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series
3天前
已完结
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
6天前
已完结
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
6天前
已关闭
Novel therapeutics and targets in myelofibrosis
6天前
已完结
Treatment of Myelofibrosis: A Moving Target
6天前
已完结
New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment
6天前
已完结
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study
9天前
已完结
Severe Pneumocystis jirovecii pneumonia: time to reassess our practices
9天前
已完结
皖公网安备34019202002308
